Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetic profile of a new (extended release) formulation of milrinone
and to demonstrate evidence of hemodynamic effect
Primary: Pharmacokinetic profile - to demonstrate stable plasma levels Secondary (HF cohort)
- to demonstrate evidence of haemodynamic benefit
Study Design: Open label